B. Monk, T. Toita, Xiaohua Wu, Juan Carlos Limón, Qi Zhou, R. Tarnawski, M. Mandai, R. Shapira-Frommer, U. Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, S. Varga, Manuel Humberto Leiva Gálvez, Jung-Yun Lee, Y. Kreynina, Kathryn Howells, S. Wildsmith, H. Dry, A. Nunes, J. Mayadev
{"title":"Durvalumab联合放化疗治疗局部晚期宫颈癌:来自3期国际随机、双盲、安慰剂对照的calla试验的结果","authors":"B. Monk, T. Toita, Xiaohua Wu, Juan Carlos Limón, Qi Zhou, R. Tarnawski, M. Mandai, R. Shapira-Frommer, U. Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, S. Varga, Manuel Humberto Leiva Gálvez, Jung-Yun Lee, Y. Kreynina, Kathryn Howells, S. Wildsmith, H. Dry, A. Nunes, J. Mayadev","doi":"10.1136/ijgc-2022-igcs.3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":348678,"journal":{"name":"Oral Abstracts (Regular and Late-Breaking Submission)","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial\",\"authors\":\"B. Monk, T. Toita, Xiaohua Wu, Juan Carlos Limón, Qi Zhou, R. Tarnawski, M. Mandai, R. Shapira-Frommer, U. Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, S. Varga, Manuel Humberto Leiva Gálvez, Jung-Yun Lee, Y. Kreynina, Kathryn Howells, S. Wildsmith, H. Dry, A. Nunes, J. Mayadev\",\"doi\":\"10.1136/ijgc-2022-igcs.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":348678,\"journal\":{\"name\":\"Oral Abstracts (Regular and Late-Breaking Submission)\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Abstracts (Regular and Late-Breaking Submission)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-igcs.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Abstracts (Regular and Late-Breaking Submission)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-igcs.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial